"I love Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer and other malignant diseases"

2022-08-05 07:14:13

HomeAbout ApogenixCompany ProfileManagement BoardSupervisory BoardInvestorsScientific AdvisorsPartneringCareersImmuno-OncologyImmuno-Oncology OverviewTNF/TNFR SuperfamilyHERA-Ligand TechnologyViral InfectionsPipelinePipelineClinical CandidatesPreclinical CandidatesScientific PublicationsClinical TrialsGlioblastomaMyelodysplastic SyndromesCOVID-19News & EventsPress ReleasesApogenix in the NewsApogenix at EventsContactContact UsLocation & DirectionsNext GenerationImmunotherapeuticsApogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.>> More about COVID-19>> More about immuno-oncologyAsunercept Clinical Development in Three IndicationsOur lead immunotherapy candidate asunercept is in clinical development for the treatment of solid tumors, malignant hematological diseases, and COVID-19. It has shown significant improvements in progression-free survival and quality of life as well as a positive trend in overallsurvival in a controlled phase II proof-of-concept trial in recurrent glioblastoma. In a phase I trial in myelodysplastic syndromes (MDS), treatment with asunercept led to a decrease in transfusion frequency in 40 percent of patients during the duration of the trial....Technology The Apogenix team has createdthe HERA-ligand technology platform for the development of novel receptor agoniststhat target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology....News December 15, 2021"Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study" published in Scientific ReportsDecember 9, 2021Apogenix Receives €20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19... Privacy StatementImprintContact